nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—S-Adenosylmethionine—GNMT—liver cancer	0.0336	0.343	CrCbGaD
Vidarabine—Electrocardiogram ST segment depression—Epirubicin—liver cancer	0.027	0.0384	CcSEcCtD
Vidarabine—Electrocardiogram ST segment depression—Doxorubicin—liver cancer	0.025	0.0355	CcSEcCtD
Vidarabine—Adenosine triphosphate—TNK2—liver cancer	0.0208	0.212	CrCbGaD
Vidarabine—Myocardial ischaemia—Sorafenib—liver cancer	0.0207	0.0294	CcSEcCtD
Vidarabine—Blood pressure increased—Sorafenib—liver cancer	0.0166	0.0236	CcSEcCtD
Vidarabine—Supraventricular extrasystoles—Epirubicin—liver cancer	0.0165	0.0234	CcSEcCtD
Vidarabine—Supraventricular extrasystoles—Doxorubicin—liver cancer	0.0152	0.0217	CcSEcCtD
Vidarabine—Sinus tachycardia—Epirubicin—liver cancer	0.0152	0.0216	CcSEcCtD
Vidarabine—Sinus tachycardia—Doxorubicin—liver cancer	0.0141	0.02	CcSEcCtD
Vidarabine—Cardiac failure—Sorafenib—liver cancer	0.0124	0.0176	CcSEcCtD
Vidarabine—Glucosamine—MMP9—liver cancer	0.0116	0.118	CrCbGaD
Vidarabine—Mood swings—Sorafenib—liver cancer	0.0114	0.0162	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—SLC11A2—liver cancer	0.0107	0.0539	CbGpPWpGaD
Vidarabine—Abdominal discomfort—Sorafenib—liver cancer	0.00999	0.0142	CcSEcCtD
Vidarabine—Acute coronary syndrome—Sorafenib—liver cancer	0.00916	0.013	CcSEcCtD
Vidarabine—Myocardial infarction—Sorafenib—liver cancer	0.00911	0.0129	CcSEcCtD
Vidarabine—Hyperventilation—Epirubicin—liver cancer	0.00892	0.0127	CcSEcCtD
Vidarabine—Burning sensation—Epirubicin—liver cancer	0.00884	0.0126	CcSEcCtD
Vidarabine—Ventricular arrhythmia—Epirubicin—liver cancer	0.00829	0.0118	CcSEcCtD
Vidarabine—Hyperventilation—Doxorubicin—liver cancer	0.00825	0.0117	CcSEcCtD
Vidarabine—Burning sensation—Doxorubicin—liver cancer	0.00818	0.0116	CcSEcCtD
Vidarabine—Scotoma—Epirubicin—liver cancer	0.00808	0.0115	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—SIX3—liver cancer	0.00781	0.0394	CbGpPWpGaD
Vidarabine—Tinnitus—Sorafenib—liver cancer	0.00778	0.011	CcSEcCtD
Vidarabine—Cardiac disorder—Sorafenib—liver cancer	0.00774	0.011	CcSEcCtD
Vidarabine—Flushing—Sorafenib—liver cancer	0.00774	0.011	CcSEcCtD
Vidarabine—Ventricular arrhythmia—Doxorubicin—liver cancer	0.00767	0.0109	CcSEcCtD
Vidarabine—Glucosamine—TNF—liver cancer	0.0076	0.0776	CrCbGaD
Vidarabine—Mediastinal disorder—Sorafenib—liver cancer	0.00752	0.0107	CcSEcCtD
Vidarabine—Scotoma—Doxorubicin—liver cancer	0.00748	0.0106	CcSEcCtD
Vidarabine—Arrhythmia—Sorafenib—liver cancer	0.00745	0.0106	CcSEcCtD
Vidarabine—Adenosine triphosphate—AKT1—liver cancer	0.00744	0.076	CrCbGaD
Vidarabine—Dysgeusia—Sorafenib—liver cancer	0.00711	0.0101	CcSEcCtD
Vidarabine—Adenosine triphosphate—ABL1—liver cancer	0.00703	0.0718	CrCbGaD
Vidarabine—Ventricular extrasystoles—Epirubicin—liver cancer	0.0068	0.00965	CcSEcCtD
Vidarabine—Angioedema—Sorafenib—liver cancer	0.00664	0.00942	CcSEcCtD
Vidarabine—Syncope—Sorafenib—liver cancer	0.00651	0.00925	CcSEcCtD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CTNNB1—liver cancer	0.0064	0.0323	CbGpPWpGaD
Vidarabine—Loss of consciousness—Sorafenib—liver cancer	0.00638	0.00907	CcSEcCtD
Vidarabine—Cough—Sorafenib—liver cancer	0.00634	0.009	CcSEcCtD
Vidarabine—Atrioventricular block—Epirubicin—liver cancer	0.00633	0.00899	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Doxorubicin—liver cancer	0.00629	0.00893	CcSEcCtD
Vidarabine—Hypertension—Sorafenib—liver cancer	0.00627	0.00891	CcSEcCtD
Vidarabine—Ventricular tachycardia—Epirubicin—liver cancer	0.00614	0.00872	CcSEcCtD
Vidarabine—Injection site reaction—Epirubicin—liver cancer	0.0061	0.00867	CcSEcCtD
Vidarabine—Dry mouth—Sorafenib—liver cancer	0.00605	0.00859	CcSEcCtD
Vidarabine—Anaphylactic shock—Sorafenib—liver cancer	0.00593	0.00842	CcSEcCtD
Vidarabine—Glucosamine—CYP2E1—liver cancer	0.00586	0.0598	CrCbGaD
Vidarabine—Atrioventricular block—Doxorubicin—liver cancer	0.00586	0.00832	CcSEcCtD
Vidarabine—Shock—Sorafenib—liver cancer	0.00583	0.00828	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—SERPINA1—liver cancer	0.00574	0.029	CbGpPWpGaD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—CTNNB1—liver cancer	0.00569	0.0287	CbGpPWpGaD
Vidarabine—Ventricular tachycardia—Doxorubicin—liver cancer	0.00568	0.00807	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—liver cancer	0.00565	0.00802	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0054	0.00767	CcSEcCtD
Vidarabine—Dyspnoea—Sorafenib—liver cancer	0.00528	0.00751	CcSEcCtD
Vidarabine—Pain—Sorafenib—liver cancer	0.00507	0.0072	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—ABL1—liver cancer	0.00488	0.0246	CbGpPWpGaD
Vidarabine—Urticaria—Sorafenib—liver cancer	0.00471	0.00669	CcSEcCtD
Vidarabine—Cardiac failure—Epirubicin—liver cancer	0.00457	0.00649	CcSEcCtD
Vidarabine—Cerebrovascular accident—Epirubicin—liver cancer	0.00455	0.00646	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—SIX3—liver cancer	0.00449	0.0226	CbGpPWpGaD
Vidarabine—Affect lability—Epirubicin—liver cancer	0.00439	0.00623	CcSEcCtD
Vidarabine—Hypersensitivity—Sorafenib—liver cancer	0.00437	0.0062	CcSEcCtD
Vidarabine—Asthenia—Sorafenib—liver cancer	0.00425	0.00604	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—liver cancer	0.00424	0.00602	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—liver cancer	0.00422	0.006	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—liver cancer	0.00422	0.006	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—liver cancer	0.00421	0.00598	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—liver cancer	0.00406	0.00576	CcSEcCtD
Vidarabine—S-Adenosylmethionine—CYP2E1—liver cancer	0.00401	0.041	CrCbGaD
Vidarabine—Cardiac arrest—Doxorubicin—liver cancer	0.00392	0.00557	CcSEcCtD
Vidarabine—Dizziness—Sorafenib—liver cancer	0.00392	0.00557	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—liver cancer	0.00391	0.00555	CcSEcCtD
Vidarabine—Vomiting—Sorafenib—liver cancer	0.00377	0.00535	CcSEcCtD
Vidarabine—Rash—Sorafenib—liver cancer	0.00374	0.00531	CcSEcCtD
Vidarabine—Dermatitis—Sorafenib—liver cancer	0.00373	0.0053	CcSEcCtD
Vidarabine—Headache—Sorafenib—liver cancer	0.00371	0.00527	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—ABL1—liver cancer	0.0036	0.0182	CbGpPWpGaD
Vidarabine—Pollakiuria—Epirubicin—liver cancer	0.00356	0.00505	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—ADAMTS17—liver cancer	0.00352	0.0178	CbGpPWpGaD
Vidarabine—Nausea—Sorafenib—liver cancer	0.00352	0.005	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—liver cancer	0.00343	0.00488	CcSEcCtD
Vidarabine—Sweating—Epirubicin—liver cancer	0.00329	0.00468	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—liver cancer	0.00329	0.00468	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—GSTM1—liver cancer	0.00322	0.0163	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—MAPK14—liver cancer	0.0032	0.0162	CbGpPWpGaD
Vidarabine—Drowsiness—Doxorubicin—liver cancer	0.00318	0.00451	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—liver cancer	0.00314	0.00446	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—liver cancer	0.00309	0.0156	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—KDR—liver cancer	0.00307	0.0155	CbGpPWpGaD
Vidarabine—Hypoaesthesia—Epirubicin—liver cancer	0.00307	0.00436	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—liver cancer	0.00305	0.00433	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—AHR—liver cancer	0.00297	0.015	CbGpPWpGaD
Vidarabine—Bradycardia—Doxorubicin—liver cancer	0.0029	0.00412	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—liver cancer	0.00287	0.00408	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—liver cancer	0.00286	0.00406	CcSEcCtD
Vidarabine—Flushing—Epirubicin—liver cancer	0.00286	0.00406	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—liver cancer	0.00284	0.00403	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—liver cancer	0.00278	0.00395	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—liver cancer	0.00276	0.014	CbGpPWpGaD
Vidarabine—Arrhythmia—Epirubicin—liver cancer	0.00275	0.00391	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—MAPK14—liver cancer	0.00271	0.0137	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—YIF1A—liver cancer	0.00267	0.0135	CbGpPWpGaD
Vidarabine—Tinnitus—Doxorubicin—liver cancer	0.00266	0.00378	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—liver cancer	0.00265	0.00376	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—liver cancer	0.00265	0.00376	CcSEcCtD
Vidarabine—Tension—Epirubicin—liver cancer	0.00263	0.00374	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—liver cancer	0.00263	0.00373	CcSEcCtD
Vidarabine—Nervousness—Epirubicin—liver cancer	0.00261	0.0037	CcSEcCtD
Vidarabine—Back pain—Epirubicin—liver cancer	0.0026	0.00369	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—liver cancer	0.00257	0.00365	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—liver cancer	0.00255	0.00362	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—liver cancer	0.00253	0.00359	CcSEcCtD
Vidarabine—Agitation—Epirubicin—liver cancer	0.00247	0.0035	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SHC3—liver cancer	0.00247	0.0124	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—SERPINE1—liver cancer	0.00246	0.0124	CbGpPWpGaD
Vidarabine—Tension—Doxorubicin—liver cancer	0.00244	0.00346	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—liver cancer	0.00243	0.00345	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—liver cancer	0.00241	0.00343	CcSEcCtD
Vidarabine—Syncope—Epirubicin—liver cancer	0.00241	0.00342	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—liver cancer	0.0024	0.00341	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—liver cancer	0.00237	0.00337	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—liver cancer	0.00236	0.00335	CcSEcCtD
Vidarabine—Cough—Epirubicin—liver cancer	0.00234	0.00333	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—liver cancer	0.00234	0.00332	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—liver cancer	0.00233	0.0033	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—liver cancer	0.00232	0.00329	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—liver cancer	0.00228	0.00325	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—liver cancer	0.00228	0.00324	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—liver cancer	0.00228	0.00323	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN1A—liver cancer	0.00226	0.0114	CbGpPWpGaD
Vidarabine—Discomfort—Epirubicin—liver cancer	0.00226	0.00321	CcSEcCtD
Vidarabine—Dry mouth—Epirubicin—liver cancer	0.00223	0.00317	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—liver cancer	0.00223	0.00316	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—EXOSC2—liver cancer	0.0022	0.0111	CbGpPWpGaD
Vidarabine—Palpitations—Doxorubicin—liver cancer	0.00219	0.00312	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—liver cancer	0.00219	0.00311	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—SERPINE1—liver cancer	0.00218	0.011	CbGpPWpGaD
Vidarabine—Loss of consciousness—Doxorubicin—liver cancer	0.00218	0.0031	CcSEcCtD
Vidarabine—Cough—Doxorubicin—liver cancer	0.00217	0.00308	CcSEcCtD
Vidarabine—Shock—Epirubicin—liver cancer	0.00215	0.00306	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—liver cancer	0.00215	0.00306	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—liver cancer	0.00214	0.00305	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—liver cancer	0.00214	0.00304	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—liver cancer	0.00212	0.00301	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—liver cancer	0.00211	0.003	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—liver cancer	0.00211	0.00299	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—liver cancer	0.00209	0.00297	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—liver cancer	0.00207	0.00294	CcSEcCtD
Vidarabine—Hypotension—Epirubicin—liver cancer	0.00205	0.00291	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—liver cancer	0.00203	0.00288	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.002	0.00283	CcSEcCtD
Vidarabine—Shock—Doxorubicin—liver cancer	0.00199	0.00283	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—liver cancer	0.00198	0.00281	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—liver cancer	0.00197	0.00279	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—liver cancer	0.00196	0.00278	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—liver cancer	0.00195	0.00277	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—liver cancer	0.00195	0.00277	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN2A—liver cancer	0.00194	0.0098	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—CTNNB1—liver cancer	0.00193	0.00974	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—SHC3—liver cancer	0.0019	0.00957	CbGpPWpGaD
Vidarabine—Hypotension—Doxorubicin—liver cancer	0.00189	0.00269	CcSEcCtD
Vidarabine—ADK—Metabolism—UGDH—liver cancer	0.00189	0.00955	CbGpPWpGaD
Vidarabine—Pain—Epirubicin—liver cancer	0.00187	0.00266	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00185	0.00262	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—liver cancer	0.00182	0.00258	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—liver cancer	0.00181	0.00257	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—liver cancer	0.0018	0.00256	CcSEcCtD
Vidarabine—ADK—Metabolism—EPT1—liver cancer	0.00178	0.00898	CbGpPWpGaD
Vidarabine—Urticaria—Epirubicin—liver cancer	0.00174	0.00247	CcSEcCtD
Vidarabine—Pain—Doxorubicin—liver cancer	0.00173	0.00246	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN1B—liver cancer	0.00172	0.00868	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—AHR—liver cancer	0.0017	0.0086	CbGpPWpGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—liver cancer	0.00169	0.00855	CbGpPWpGaD
Vidarabine—ADK—Metabolism—TAT—liver cancer	0.00169	0.00852	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—CDKN1A—liver cancer	0.00167	0.00841	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CCND1—liver cancer	0.00164	0.00828	CbGpPWpGaD
Vidarabine—Hypersensitivity—Epirubicin—liver cancer	0.00161	0.00229	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—liver cancer	0.00161	0.00229	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN1A—liver cancer	0.00159	0.00801	CbGpPWpGaD
Vidarabine—Asthenia—Epirubicin—liver cancer	0.00157	0.00223	CcSEcCtD
Vidarabine—ADORA2A—Monoamine Transport—TNF—liver cancer	0.00152	0.00769	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—liver cancer	0.00149	0.00212	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.00146	0.00738	CbGpPWpGaD
Vidarabine—Asthenia—Doxorubicin—liver cancer	0.00145	0.00207	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—liver cancer	0.00145	0.00206	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—TRIO—liver cancer	0.0014	0.00709	CbGpPWpGaD
Vidarabine—Vomiting—Epirubicin—liver cancer	0.00139	0.00198	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—PPARA—liver cancer	0.00139	0.00701	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—MYC—liver cancer	0.00138	0.00697	CbGpPWpGaD
Vidarabine—Rash—Epirubicin—liver cancer	0.00138	0.00196	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—liver cancer	0.00138	0.00196	CcSEcCtD
Vidarabine—Headache—Epirubicin—liver cancer	0.00137	0.00195	CcSEcCtD
Vidarabine—Dizziness—Doxorubicin—liver cancer	0.00134	0.0019	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—MYC—liver cancer	0.00132	0.00664	CbGpPWpGaD
Vidarabine—Nausea—Epirubicin—liver cancer	0.0013	0.00185	CcSEcCtD
Vidarabine—Vomiting—Doxorubicin—liver cancer	0.00129	0.00183	CcSEcCtD
Vidarabine—ADA—Metabolism—UGDH—liver cancer	0.00129	0.00649	CbGpPWpGaD
Vidarabine—Rash—Doxorubicin—liver cancer	0.00128	0.00182	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—liver cancer	0.00128	0.00181	CcSEcCtD
Vidarabine—Headache—Doxorubicin—liver cancer	0.00127	0.0018	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.00125	0.00633	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—ATF3—liver cancer	0.00123	0.00623	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—KRAS—liver cancer	0.00122	0.00614	CbGpPWpGaD
Vidarabine—ADA—Metabolism—EPT1—liver cancer	0.00121	0.00611	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—liver cancer	0.0012	0.00171	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—PPARG—liver cancer	0.00115	0.0058	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TAT—liver cancer	0.00115	0.00579	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GLUL—liver cancer	0.00115	0.00579	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CPT1B—liver cancer	0.00115	0.00579	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NR1H4—liver cancer	0.00111	0.00558	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTA3—liver cancer	0.00109	0.00549	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ADAM17—liver cancer	0.00106	0.00537	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—SERPINE1—liver cancer	0.00103	0.00522	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—HRAS—liver cancer	0.00103	0.00522	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PRKCE—liver cancer	0.00101	0.00509	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTA4—liver cancer	0.000994	0.00502	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTA2—liver cancer	0.000969	0.00489	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCR4—liver cancer	0.000954	0.00482	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTA1—liver cancer	0.000935	0.00472	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NAT2—liver cancer	0.000924	0.00467	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALDOB—liver cancer	0.000886	0.00447	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CRABP1—liver cancer	0.000845	0.00427	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—JUN—liver cancer	0.000814	0.00411	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—PPARA—liver cancer	0.000798	0.00403	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CPT1B—liver cancer	0.000779	0.00393	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GLUL—liver cancer	0.000779	0.00393	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PRKCE—liver cancer	0.000776	0.00392	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—MAPK8—liver cancer	0.00077	0.00389	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—IGF2—liver cancer	0.000765	0.00386	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NR1H4—liver cancer	0.000752	0.00379	CbGpPWpGaD
Vidarabine—ADK—Metabolism—HPGDS—liver cancer	0.000739	0.00373	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTA3—liver cancer	0.000739	0.00373	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CHN2—liver cancer	0.000727	0.00367	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK14—liver cancer	0.000722	0.00365	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTA4—liver cancer	0.000676	0.00341	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IFT88—liver cancer	0.000665	0.00336	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—PPARG—liver cancer	0.000659	0.00333	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PSMD10—liver cancer	0.000659	0.00332	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PSMA4—liver cancer	0.000659	0.00332	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTA2—liver cancer	0.000659	0.00332	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GOT2—liver cancer	0.000641	0.00323	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTA1—liver cancer	0.000635	0.00321	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—liver cancer	0.00063	0.00318	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NAT2—liver cancer	0.000628	0.00317	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP2E1—liver cancer	0.000602	0.00304	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALDOB—liver cancer	0.000602	0.00304	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—SERPINE1—liver cancer	0.000594	0.003	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—liver cancer	0.000589	0.00297	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CRABP1—liver cancer	0.000575	0.0029	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYCS—liver cancer	0.000564	0.00285	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—TRIO—liver cancer	0.000562	0.00284	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—F2—liver cancer	0.00056	0.00283	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK14—liver cancer	0.000556	0.0028	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GGT1—liver cancer	0.000553	0.00279	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GOT1—liver cancer	0.000553	0.00279	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CCR4—liver cancer	0.000539	0.00272	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TP53—liver cancer	0.000537	0.00271	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—liver cancer	0.000526	0.00265	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—liver cancer	0.000513	0.00259	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—liver cancer	0.000513	0.00259	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—TRIO—liver cancer	0.000511	0.00258	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HPGDS—liver cancer	0.000502	0.00254	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000501	0.00253	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTP1—liver cancer	0.000497	0.00251	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—IL6—liver cancer	0.000492	0.00248	CbGpPWpGaD
Vidarabine—ADK—Metabolism—HMOX1—liver cancer	0.00049	0.00247	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCR4—liver cancer	0.00049	0.00247	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—BRAF—liver cancer	0.000484	0.00244	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—liver cancer	0.000482	0.00243	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MMP2—liver cancer	0.000475	0.0024	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—JUN—liver cancer	0.000468	0.00236	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTM1—liver cancer	0.000457	0.0023	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CD—liver cancer	0.000453	0.00229	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PSMD10—liver cancer	0.000448	0.00226	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PSMA4—liver cancer	0.000448	0.00226	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—liver cancer	0.000445	0.00224	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—MAPK8—liver cancer	0.000442	0.00223	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GOT2—liver cancer	0.000435	0.0022	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP1A1—liver cancer	0.000433	0.00218	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP2E1—liver cancer	0.000409	0.00207	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SHC3—liver cancer	0.000407	0.00206	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RAF1—liver cancer	0.000404	0.00204	CbGpPWpGaD
Vidarabine—ADK—Metabolism—MTHFR—liver cancer	0.000403	0.00204	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—liver cancer	0.000397	0.002	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPARA—liver cancer	0.000396	0.002	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CB—liver cancer	0.000395	0.00199	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MTOR—liver cancer	0.000395	0.00199	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYCS—liver cancer	0.000383	0.00193	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—F2—liver cancer	0.000381	0.00193	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GGT1—liver cancer	0.000376	0.0019	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GOT1—liver cancer	0.000376	0.0019	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1B—liver cancer	0.00037	0.00187	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CTNNB1—liver cancer	0.000364	0.00184	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—liver cancer	0.000363	0.00183	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1A—liver cancer	0.000342	0.00173	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—liver cancer	0.000341	0.00172	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CG—liver cancer	0.000339	0.00171	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTP1—liver cancer	0.000338	0.0017	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK8—liver cancer	0.000334	0.00168	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HMOX1—liver cancer	0.000333	0.00168	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPARG—liver cancer	0.000327	0.00165	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FST—liver cancer	0.000316	0.0016	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—liver cancer	0.000313	0.00158	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PRKCE—liver cancer	0.000311	0.00157	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTM1—liver cancer	0.00031	0.00157	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—liver cancer	0.000309	0.00156	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—STAT3—liver cancer	0.000305	0.00154	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TRIO—liver cancer	0.000302	0.00152	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CD—liver cancer	0.000298	0.0015	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1A1—liver cancer	0.000294	0.00149	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALB—liver cancer	0.000294	0.00149	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—liver cancer	0.000289	0.00146	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCR4—liver cancer	0.000289	0.00146	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—liver cancer	0.000283	0.00143	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PRKCE—liver cancer	0.000282	0.00142	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—liver cancer	0.000277	0.0014	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CSF2—liver cancer	0.000275	0.00139	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTHFR—liver cancer	0.000274	0.00138	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPARA—liver cancer	0.000269	0.00136	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—liver cancer	0.000262	0.00132	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CB—liver cancer	0.00026	0.00131	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—liver cancer	0.000256	0.00129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CSF2—liver cancer	0.000249	0.00126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—liver cancer	0.000241	0.00121	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CG—liver cancer	0.00023	0.00116	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADAM17—liver cancer	0.000229	0.00115	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—liver cancer	0.000223	0.00112	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPARG—liver cancer	0.000222	0.00112	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—F2—liver cancer	0.000216	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSMD10—liver cancer	0.000215	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSMA4—liver cancer	0.000215	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—liver cancer	0.000213	0.00108	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CG—liver cancer	0.000206	0.00104	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CD—liver cancer	0.000203	0.00102	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALB—liver cancer	0.0002	0.00101	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—liver cancer	0.000197	0.000992	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—F2—liver cancer	0.000196	0.000988	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CG—liver cancer	0.000187	0.000946	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CD—liver cancer	0.000181	0.000915	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CB—liver cancer	0.000177	0.000891	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRKCE—liver cancer	0.000167	0.000841	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CD—liver cancer	0.000165	0.000831	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—liver cancer	0.000158	0.000799	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CB—liver cancer	0.000158	0.000798	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF2—liver cancer	0.000158	0.000797	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CSF2—liver cancer	0.000147	0.000744	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RAF1—liver cancer	0.000147	0.000742	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—H2AFX—liver cancer	0.000145	0.000733	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—liver cancer	0.000145	0.000733	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CB—liver cancer	0.000144	0.000725	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—liver cancer	0.000132	0.000665	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TERT—liver cancer	0.000131	0.000663	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—liver cancer	0.000129	0.000653	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KDR—liver cancer	0.00012	0.000606	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK14—liver cancer	0.000119	0.000602	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ESR1—liver cancer	0.000117	0.000591	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—F2—liver cancer	0.000116	0.000584	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CG—liver cancer	0.000111	0.000559	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APC—liver cancer	0.000111	0.000559	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—liver cancer	0.000108	0.000543	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BRAF—liver cancer	0.000104	0.000525	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CD—liver cancer	9.73e-05	0.000491	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—liver cancer	9.64e-05	0.000486	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SERPINE1—liver cancer	9.62e-05	0.000486	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—liver cancer	9.52e-05	0.000481	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—liver cancer	8.79e-05	0.000444	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—liver cancer	8.75e-05	0.000442	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RAF1—liver cancer	8.68e-05	0.000438	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MTOR—liver cancer	8.48e-05	0.000428	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CB—liver cancer	8.48e-05	0.000428	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—liver cancer	8.1e-05	0.000409	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1B—liver cancer	7.96e-05	0.000402	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—liver cancer	7.87e-05	0.000397	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—liver cancer	7.8e-05	0.000394	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—liver cancer	7.79e-05	0.000393	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—liver cancer	7.75e-05	0.000391	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—liver cancer	7.59e-05	0.000383	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUN—liver cancer	7.58e-05	0.000382	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNB1—liver cancer	7.52e-05	0.000379	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—liver cancer	7.37e-05	0.000372	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1A—liver cancer	7.34e-05	0.000371	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK8—liver cancer	7.17e-05	0.000362	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—liver cancer	7.15e-05	0.000361	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—liver cancer	6.62e-05	0.000334	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT3—liver cancer	6.55e-05	0.000331	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—liver cancer	6.09e-05	0.000307	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—liver cancer	6.07e-05	0.000307	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—liver cancer	5.63e-05	0.000284	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—liver cancer	5.17e-05	0.000261	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—liver cancer	5e-05	0.000252	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—liver cancer	4.78e-05	0.000241	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—liver cancer	4.58e-05	0.000231	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—liver cancer	4.22e-05	0.000213	CbGpPWpGaD
